Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2024-10-30 00:00:00 ET · period of report 2024-10-30 · accession 0001549595-24-000146 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-30 | 2024-10-30 | NRIX | Ring Christine | CLO | S - Sale+OE | $24.31 | -4,182 | 28.1K | -13% | -$101.7K |
| DM | 2024-10-30 | 2024-10-30 | NRIX | Ring Christine | CLO | M - OptEx | $0.00 | +7,674 | 26.5K | +41% | $0 |
| DM | 2024-10-30 | 2024-10-30 | NRIX | Ring Christine | CLO | M - OptEx | $0.00 | -7,674 | 9,621 | -44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-30 | S | D | 4,182 | $24.31 | 28,084 | D | — | — | (F2) Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Stock | 2024-10-30 | M | A | 3,750 | $0.00 | 32,266 | D | — | — | |
| 3 | Common | Common Stock | 2024-10-30 | M | A | 2,000 | $0.00 | 28,516 | D | — | — | |
| 4 | Common | Common Stock | 2024-10-30 | M | A | 1,924 | $0.00 | 26,516 | D | — | — | |
| 5 | Derivative | Restricted Stock Units | 2024-10-30 | M | D | 2,000 | $0.00 | 12,000 | D | $0.00 · — to — | 2,000 Common Stock | (F3) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. (F6) The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. (F5) RSUs do not expire; they either vest or are canceled prior to the vest date. |
| 6 | Derivative | Restricted Stock Units | 2024-10-30 | M | D | 3,750 | $0.00 | 37,500 | D | $0.00 · — to — | 3,750 Common Stock | (F3) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. (F7) The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. (F5) RSUs do not expire; they either vest or are canceled prior to the vest date. |
| 7 | Derivative | Restricted Stock Units | 2024-10-30 | M | D | 1,924 | $0.00 | 9,621 | D | $0.00 · — to — | 1,924 Common Stock | (F3) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. (F4) The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. (F5) RSUs do not expire; they either vest or are canceled prior to the vest date. |